Highlights Carisma Therapeutics, Inc.

Equities

CARM

US14216R1014

Market Closed - Nasdaq Other stock markets 01:30:00 11/05/2024 am IST			5-day change	1st Jan Change
1.48 ^USD	-1.99%		-8.64%	-49.49%

09/05	Carisma Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02/05	Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Carisma Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Carisma Therapeutics Q4 Net Loss Narrows, Revenue Rises; Plans Job Cuts in Q2 -- Shares Decline	02/04	MT
Carisma Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04	CI
Carisma Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01/04	CI
North American Morning Briefing : Inflation Data -2-	12/03	DJ
Carisma Therapeutics Obtains FDA Clearance to Study Potential Solid Tumor Therapy	28/11	MT
Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte	28/11	CI
Carisma Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
Carisma Therapeutics Inc. Presents Pre-Clinical Proof of Concept for in vivo CAR-M Using mRNA Platform in Collaboration with Moderna at SITC	31/23/31	CI
Carisma Therapeutics Inc. to Present First Results from in Vivo Car-M Collaboration with Moderna at SITC 2023	25/23/25	CI
Carisma Therapeutics, Inc. Announces Latest Data from Phase 1 Clinical Trial of CT-0508 At 8th Annual CAR-TCR Summit	01/23/01	CI
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with Keytruda(R) (Pembrolizumab) in Patients with Her2 Overexpressing Solid Tumors	28/23/28	CI
Carisma Therapeutics Inc. Provides Pipeline Updates	13/23/13	CI
Carisma Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11	CI
Carisma Therapeutics Closes Merger with Sesen Bio	08/23/08	AQ
CARISMA Therapeutics Inc. completed the acquisition of Sesen Bio, Inc. from The Vanguard Group, Inc., JEC II Associates, LLC, BML Investment Partners, L.P. managed by BML Capital Management, LLC and others in a reverse merger transaction.	07/23/07	CI
Sesen Bio Gets Shareholders Nod for Carisma Therapeutics Merger, to Pay Special Dividend	02/23/02	MT
Sesen Bio Stockholders Approve Merger with Carisma Therapeutics	02/23/02	BU
SESEN BIO, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	28/23/28	AQ
Sesen Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	28/23/28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Carisma Therapeutics, Inc.

Equities

CARM

US14216R1014

Highlights

Filters